We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effects of Kneehab 12-week Peri-operative Total Knee Arthroplasty (KneehabTKA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01096524
Recruitment Status : Completed
First Posted : March 31, 2010
Last Update Posted : July 21, 2014
Royal Liverpool and Broadgreen University Hospitals NHS Trust
Information provided by (Responsible Party):
Bio-Medical Research, Ltd.

March 24, 2010
March 31, 2010
July 21, 2014
March 2010
June 2014   (Final data collection date for primary outcome measure)
Efficacy of Kneehab in promoting early recovery of quadriceps performance following knee arthoplasty. [ Time Frame: 6 weeks Pre-Op and 6, 12 and 52 weeks post op. ]

Isometric muscle strength of the knee extensors will be measured by dynamometer with the knee flexed to 60°.

Functional ability will be measured using the Timed Get Up and Go (TUG) and Stair Climb Test (SCT).

Same as current
Complete list of historical versions of study NCT01096524 on ClinicalTrials.gov Archive Site
Determine the effect of Kneehab in promoting quality of life measures and health economic outcomes, compared to controls. [ Time Frame: 6 Weeks pre-Op and 6, 12 and 52 weeks post-Op ]
Administration of the Western Ontario McMaster University Osteoarthritis Index (WOMAC) and The Medical Outcomes Survey (SF-12). Health economic data will include patient length of stay post surgery; number of outpatient physiotherapy visits in the following year, and change in analgesic medication use during the 6 weeks pre- and 12 weeks post surgery.
Same as current
Not Provided
Not Provided
Effects of Kneehab 12-week Peri-operative Total Knee Arthroplasty
Phase III Study Investigating the Effects of 6-weeks of Neuromuscular Electrical Stimulation (NMES) Peri-total Knee Arthroplasty (TKA).
Determine the efficacy of neuromuscular electrical stimulation (NMES, Kneehab) in promoting accelerated recovery of quadriceps function in patients recovering from total knee arthroplasty (TKA) as measured by increases in isometric strength of the knee extensors and scores in the Timed Up and Go (TUG) test.

Knee osteoarthritis is a severe debilitating condition that greatly impacts patient quality of life, function, emotional well-being and everyday pain levels. Total knee arthroplasty (TKA) is performed as a means of alleviating these symptoms in the long term however short term muscle weakness following surgery can elicit its own detrimental effect on performance and activities of daily living. This underlines the importance of mitigating strength loss in the immediate post-operative period.

Recent reviews suggest that Neuromuscular Electrical Stimulation (NMES) of the quadriceps femoris muscle can be beneficial in the rehabilitation period following knee surgery. It appears that early use of NMES can help to recover exercise capacity in the muscle, thus allowing the patient to benefit more from volitional exercise therapy later in the rehabilitation period1. This in turn can lead to accelerated recovery and improved outcomes. A recent and as yet unpublished study of 96 patients following ACL reconstruction has demonstrated a clear benefit to the use of Kneehab. The benefit seemed to accrue in the six-week post-operative period.

A recent pilot study by Walls 2 also suggests that NMES applied in the immediate pre-operative period before TKA leads to increased muscle strength and improved functional abilities. Previously, Mizner (2005) has shown pre operative strength to be a good predictor of functional outcome 1 year after surgery3. This proposed study aims to examine whether NMES applied in the peri-operative timeframe, 6 weeks before and 6 weeks after, can improve outcomes for patients undergoing total knee replacement. The rationale for this approach is that NMES can help prepare the quadriceps muscle for the rehabilitation phase by building exercise capacity before the operation. The immediate deficit, which normally follows knee surgery, would therefore be compensated to some extent and the post-operative NMES treatment would be expected to counteract the activation inhibition that is thought to occur in the early weeks following surgery. Overall, the patient would be in a better position to benefit from conventional rehabilitation exercises aimed at improved co-ordination and functional performance.

Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
  • Knee Osteoarthritis
  • Disuse Atrophy
  • Other: Standard Physiotherapy
    The Control group will complete the standard physiotherapy care pre and post-TKA surgery without NMES.
  • Device: Kneehab

    NMES 2 x 20 minute sessions/day, 5 days/week, 6 weeks pre and 6 weeks post TKA.

    Kneehab™ (Bio-Medical Research, Ltd., Galway, Ireland) is a NMES device with Multipath™ technology, designed to activate the quadriceps muscle. Kneehab™ is a battery operated, portable, 2-channel cutaneous electrical muscle stimulator, which operates using constant current pulses to stimulate the nerves innervating the quadriceps muscle. Kneehab™, consists of a thigh wrap with anatomically shaped electrodes and a control unit. Electrodes are placed over the quadriceps muscles and the garment is wrapped around the leg above the knee. Brief electrical impulses are delivered through the skin surface adhesive electrodes.

    Other Names:
    • Neuromuscular Electrical Stimulation
    • NMES
  • Control group standard physiotherapy
    Standard pathway of care pre-and post-TKA without using NMES.
    Intervention: Other: Standard Physiotherapy
  • Experimental: Kneehab
    Kneehab on the quadriceps of the affected leg, 20 minutes, twice per day, 5 days per week over 12-week intervention (6 weeks pre-op, 6 weeks post op).
    Intervention: Device: Kneehab

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
June 2014
June 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Individuals who are scheduled for elective Total Knee Replacement surgery
  • Individuals who are at least 18 years of age
  • Individuals with a body mass index (BMI) <40
  • Individuals who are walking independently with or without assistive devices
  • Must be able and willing to complete all study assessments and to be followed for the full course of the study.
  • Must be able to read, write and follow instructions in English.
  • Must be able and willing to provide informed consent.
  • Must be willing and able to attend for pre-op assessment

Exclusion Criteria:

  • Individuals who have failed the pre-operative assessment
  • Individuals with a history of foot and/or ankle pathology
  • Individuals with a history of tibial or femoral fractures
  • Individuals with a history of underlying neurological conditions
  • Individuals with physical conditions which would make them unable to perform study procedures
  • Individuals with a total hip replacement
  • Individuals undergoing revision TKA of the same operated leg
  • Pregnant women or inadequate precautions to prevent pregnancy
  • Diagnosis of a medical condition that would contraindicate treatment with the product,e.g skin lesions at electrode site.
  • Individuals with an active implanted medical device (i.e. pacemaker, pump)
  • Individuals with a history of stroke
  • Individuals with a history of neurological disorder that affects lower extremity function (stroke, peripheral neuropathy, Parkinson's disease, multiple sclerosis, etc.)
  • Individuals with a diagnosis of inflammatory arthritis (including Rheumatoid Arthritis, gout or psoriatic arthritis)
  • Individuals with muscle disease (i.e. muscular dystrophy)
  • Visible skin injury or disease on their legs
  • Principal investigator for this study, or member of study staff
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
2008-008483-27 ( EudraCT Number )
Not Provided
Not Provided
Bio-Medical Research, Ltd.
Bio-Medical Research, Ltd.
Royal Liverpool and Broadgreen University Hospitals NHS Trust
Principal Investigator: Alasdair Santini, M.D. Royal Liverpool & Broadgreen University Hospital
Bio-Medical Research, Ltd.
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP